Australia markets closed

Takeda Pharmaceutical Company Limited (TAK)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
17.47+0.03 (+0.17%)
At close: 4:00PM EST

17.40 -0.07 (-0.40%)
After hours: 6:06PM EST

Takeda Pharmaceutical Company Limited

1-1, Nihonbashi-Honcho 2-chome
Tokyo 103-8668
81 3 3278 2306

IndustryDrug Manufacturers—Specialty & Generic
Full-time employees47,495

Key executives

NameTitlePayExercisedYear born
Mr. Christophe WeberPres, CEO & Representative DirectorN/AN/A1966
Mr. Constantine SaroukosCFO & DirectorN/AN/A1971
Mr. Masato IwasakiPres of Japan Pharma Bus. Unit & DirectorN/AN/A1958
Dr. Andrew S. PlumpPres of R&D and DirectorN/AN/A1965
Dr. Seigo IzumoChair of Management BoardN/AN/AN/A
Mr. Haruhiko HirateMember of Management BoardN/AN/A1957
Salvatore AlesciMember of Management Board and Head of R&D Global Science & Biomedical PolicyN/AN/AN/A
Mr. Iwaaki TaniguchiSr. VP of Corp. Fin. & Controlling DepartmentN/AN/AN/A
Mr. Christopher David O'ReillyGlobal Head of Investor Relations & Global Fin.N/AN/AN/A
Mr. Yoshihiro NakagawaGlobal Gen. CounselN/AN/A1960
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a corporate strategic research alliance with Egle Therapeutics SAS; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; and strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Corporate governance

Takeda Pharmaceutical Company Limited’s ISS governance QualityScore as of 3 December 2020 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 5; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.